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The last two decades have seen dramatic progress in relaps-
ing–remitting multiple sclerosis (RRMS). Experimental 
autoimmune encephalomyelitis (EAE) and other animal 
models have provided insights into the pathophysiology of 
central nervous system inflammation and demyelination. 
Clinical diagnostic criteria have been refined, and 
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Abstract
Despite significant progress in the development of therapies for relapsing MS, progressive MS remains comparatively 
disappointing. Our objective, in this paper, is to review the current challenges in developing therapies for progressive MS 
and identify key priority areas for research.  A collaborative was convened by volunteer and staff leaders from several MS 
societies with the mission to expedite the development of effective disease-modifying and symptom management therapies 
for progressive forms of multiple sclerosis. Through a series of scientific and strategic planning meetings, the collaborative 
identified and developed new perspectives on five key priority areas for research: experimental models, identification and 
validation of targets and repurposing opportunities, proof-of-concept clinical trial strategies, clinical outcome measures, 
and symptom management and rehabilitation. Our conclusions, tackling the impediments in developing therapies for 
progressive MS will require an integrated, multi-disciplinary approach to enable effective translation of research into 
therapies for progressive MS. Engagement of the MS research community through an international effort is needed to 
address and fund these research priorities with the ultimate goal of expediting the development of disease-modifying and 
symptom-relief treatments for progressive MS.
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biomarkers are being developed that predict future disease 
activity and disability. A clear pathway has emerged for 
developing RRMS therapies: studies in experimental mod-
els, Phase I safety studies, Phase II trials with active MRI 
lesions as the primary outcome, and finally Phase III trials 
using relapses and sustained progression of disability as 
primary outcome. Eight disease-modifying therapies have 
received regulatory approval for RRMS and several more 
are in late-stage clinical development and could receive 
regulatory approval shortly.
For all the success in developing treatments for RRMS, 
the story in progressive MS is comparatively disappointing 
and more challenging. Even the definition of progressive 
MS has been elusive. At the clinical level, progressive MS 
is defined as the gradual progression of clinical disability 
in a patient either with a preceding relapsing course (sec-
ondary progressive MS, SPMS) or without a preceding 
relapsing course (primary progressive MS, PPMS).1 There 
may be superimposed evidence of overt inflammation, but 
frequent relapses and many new lesions on MRI are more 
suggestive of RRMS. At the imaging level, progressive MS 
is the gradual accumulation of imaging abnormalities. At 
the pathology level, progressive MS is the abnormal pro-
cesses present in neurons or glial cells that lead to irrevers-
ible injury that causes clinical disability progression. An 
inherent difficulty in studying progressive MS is the indis-
tinct overlap with RRMS, with the pathologic origins of 
progressive MS probably developing much earlier than its 
clinical manifestations. Here, PPMS and SPMS are grouped 
together, since they share many similarities – clinically, 
pathologically, and particularly as revealed by imaging 
technology.2
Animal models such as EAE provide only limited insight 
into the pathophysiology of progressive MS. New MRI 
lesions are only occasionally seen in progressive MS, 
resulting in uncertainty as to which imaging or other bio-
marker should be employed in Phase II proof-of-concept 
clinical trials. The clinical metrics used in RRMS have 
unclear sensitivity in progressive MS, limiting their utility. 
Mechanisms for identifying candidate therapies among 
existing therapies are not well defined.
Clinical trials of anti-inflammatory therapies in progres-
sive MS have been generally negative or inconsistent. 
Immunosuppressive and immunomodulating drugs such as 
cladribine, azathioprine, and cyclophosphamide have 
shown no evidence for efficacy in SPMS and PPMS. Only 
mitoxantrone has been approved for SPMS in some coun-
tries, and this treatment has a serious adverse effect profile. 
Finally, early attempts to approach progressive MS with 
putative neuroprotective therapies have failed, as seen in 
the recent trial of lamotrigine.3
Given the challenges presented by progressive MS, a 
collaborative was convened by volunteer and staff leaders 
from several MS societies ‘to expedite the development of 
effective disease-modifying and symptom management 
therapies for progressive forms of multiple sclerosis’. 
Through a series of scientific and strategic planning meet-
ings, five key priority areas for research were identified 
(Table 1). These areas represent opportunities where con-
certed research efforts would provide significant impact in 
overcoming the current barriers in developing effective 
treatments for progressive MS and provide a clear roadmap 
for the future.
Experimental models
Experimental models for MS have provided important 
insights into disease pathogenesis and potential therapies.4 
Neurotoxicity models inform neuroprotection strategies 
that may prevent neurodegeneration in MS.4 The three 
most commonly studied animal models in MS are: EAE, 
virally induced demyelinating disease models and toxin-
induced models of demyelination.5 Despite their extensive 
use, the clinical course, immunology and neuropathology 
of these models reflect only part of the pathophysiological 
spectrum of human MS.4,6 Therefore, direct extrapolation 
of results obtained in these models to MS is often tenuous, 
and the effect of therapeutic interventions in animals must 
be interpreted with care.7 In addition, most of the current 
models follow a monophasic episode of inflammation and 
therefore predominantly mirror only the impact of acute 
inflammation and neuronal injury seen in RRMS.4,6
Several animal models claim to represent human pro-
gressive MS,8 but few offer compelling evidence.6 The 
chronicity of these models is usually short and the compo-
sition of lesions different from MS.6 Furthermore, most of 
these models do not reflect the irreversible deficits charac-
terizing progressive MS.9
Therefore, there is an urgent need for better animal mod-
els that reproduce the key clinical and pathological features 
of SPMS and PPMS. Such models should include the role of 
CD8-positive T cells and notably macrophages, which com-
prise a major component in progressive MS lesions. Ectopic 
B cell follicles should be studied as an alternative disease-
related mechanism. Additional models are also needed that 
demonstrate robust chronic demyelination and neurode-
generation, such as an autoimmune-independent, inflam-
matory glial cell-associated neurodegeneration, which 
more accurately reflects progressive MS. In addition to 
animal models, brain-slice cultures that demonstrate 
demyelination and neurodegeneration may be informative, 
Table 1. Five key research priorities for progressive MS.
- Experimental Models
-  Identification and Validation of Targets and Repurposing 
Opportunities
- Proof-of-Concept Clinical Trial Strategies
- Clinical Outcome Measures
- Symptom Management and Rehabilitation
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especially if they can be adapted to use human post-mor-
tem tissue where MS pathology can be directly examined.
Identification and validation of targets 
and repurposing opportunities
While our understanding of the pathophysiology of pro-
gressive MS is yielding knowledge which can be applied to 
the development of new treatments, identifying and validat-
ing targets for use in drug discovery for progressive MS 
remains a significant challenge. Helpful insights may come 
from genome-wide association studies (GWAS). Since the 
first non-MHC susceptibility locus (IL2RA) was identi-
fied,10 the list of MS risk loci is growing, with around 50 
loci identified to date.11 However, no individual gene vari-
ant has been identified as the ideal therapeutic target and, 
even when considering all disease-associated variants 
together, risk loci explain only a modest fraction of disease 
heritability.12 Notwithstanding these limitations, the avail-
able results may suffice for computational and systems 
biology analyses to provide novel insights into biological 
pathways involved in disease pathogenesis. Indeed, compu-
tational biology is shifting from diagrammatic representa-
tion of pathways to mathematical models. These techniques 
hold promise to provide the tools for interpreting genetic 
data across different knowledge domains.13 Furthermore, 
systematic assessments of the functional consequences of 
the associated variants are underway. Together, the results 
of these studies could help prioritize putative therapeutic 
targets and steer the development of new compounds.
In addition, methods have recently been developed to 
select old drugs for new targets. Historically, repositioning 
of a compound for a new indication has been a chance 
occurrence, driven by observations of unforeseen favorable 
effects. Now there is intense research on how to systemati-
cally infer new therapeutic targets for drugs that have 
already been registered for human use. Side-effect or chem-
ical similarities between drugs and ligand sets are examples 
of this new strategy.14,15 These data may be further refined 
through screenings of registered drugs on cellular and ani-
mal models of MS.
Superimposing biologically relevant pathways identi-
fied through GWAS studies to ‘catalogues’ of pheno-
typic effects of registered drugs may shorten the process 
of identifying therapies with potential efficacy in 
progressive MS. This strategy is safe for patients, 
since repurposed drugs usually come with years of post-
marketing experience in other diseases. This strategy is 
also cost-effective, since it streamlines preclinical and 
early-stage clinical studies. Indeed, the latest GWAS 
data did not show substantial differences at susceptibil-
ity loci between relapsing and primary progressive forms 
of MS, suggesting relevance of GWAS results to pro-
gressive MS.11
The therapeutic opportunities that come from GWAS, 
computational biology and systematic reassessment of the 
effects of pharmaceutical compounds need further develop-
ment to achieve their potential application to progressive 
MS. Intellectual property and the possibility of re-evaluat-
ing compounds that have not made it through the approval 
process are among the issues that, if properly addressed, 
may help accelerate the development of effective therapies 
for progressive MS.16
Proof-of-concept clinical trial 
strategies
Agents for which there is promising preclinical data need to 
be developed through early phase clinical trials for evi-
dence of safety and therapeutic benefit. Phase II trials gen-
erally rely on biomarkers that are more sensitive to 
therapeutic effects than clinical measures. Biomarker out-
comes enable Phase II trials to be shorter and have a smaller 
sample size than Phase III trials.
Valid surrogate biomarkers need to predict clinical out-
comes. Phase II trials in RRMS have advanced because 
lesion activity on MRI is an accepted biomarker of clinical 
relapse rate.17 In contrast, no comparable measure has been 
identified in progressive MS. There are no agreed imaging 
markers of neurodegenerative processes such as energy 
failure, ionic imbalances and loss of neuronal integrity. The 
problem is compounded by limitations of clinical measures 
of disease progression against which any biomarker might 
be validated.
At present, promising imaging metrics include cerebral 
and spinal cord atrophy, lesion T1 hypointensity, magneti-
zation transfer ratio to assess lesion microstructure, and 
optical coherence tomography to measure axonal degenera-
tion in the retina.18 There is enough longitudinal data to 
enable sample sizes to be calculated for most of these tech-
niques for proof-of-concept trials, but their sensitivity to 
change and responsiveness to treatment is not well under-
stood. Newer techniques that assess tissue microstructure 
are also candidate metrics, including diffusion tensor imag-
ing19 in addition to methods that can derive axonal density 
and radius. Techniques that examine earlier events in the 
injury pathway include sodium imaging20 and measure-
ments of metabolic markers, including the neuronal/mito-
chondrial marker N-acetylaspartate.21 These techniques 
could be complemented and extended by positron emission 
tomography (PET).22 Little is known about the sensitivity, 
responsiveness and predictive power of most of these imag-
ing techniques and their limited availability may restrict 
their widespread use.
A number of tissue fluid biomarkers have been studied, 
mostly to assess immunological activity. Markers of spe-
cific injury mechanisms are also emerging, including 
chemokines associated with intrathecal B lymphocyte 
activity that might drive cortical injury,23 nitric oxide 
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metabolites,24 and neurofilaments released by damaged 
axons.25 A significant drawback to widespread application 
of these biomarkers is their typical measurement from cer-
ebrospinal fluid, which is not easily accessible. Nonetheless, 
cerebrospinal fluid is increasingly incorporated into designs 
of progressive MS trials, and efforts to identify biomarkers 
in plasma and serum are underway.
Better biomarkers would power smaller and shorter tri-
als. More flexible trial designs are also being examined to 
achieve the same aim. These include modified entry criteria 
to enrich trials for patients more likely to progress. Adaptive 
designs such as those used in cancer trials could make use 
of prognostic biomarkers to stratify an outcome analysis 
that is sensitive to subpopulation treatment effects,26 and 
could employ an interim futility analysis to exclude non-
effective agents.27
These considerations suggest that proof-of-concept clin-
ical trial strategies are likely to evolve significantly if (1) 
biomarkers can be identified and validated that measure 
important events in the neuronal injury pathway, are relia-
ble, easily implemented, dynamic over time, and correlate 
with disability, and (2) if trial designs can be developed 
which further minimize trial size and duration. Importantly, 
these innovations will need sufficient community consen-
sus to be accepted by regulatory authorities.
Clinical outcome measures
A critical aspect in the development of therapies is a meas-
urement tool of therapeutic efficacy. The ideal measure-
ment tool is precise, reproducible, broad-based in its 
assessment, sensitive to change over time, and predictive of 
future change. The evaluation of MS therapies in RRMS 
was greatly assisted by clear definitions and objective 
measurement of clinical relapses. Establishing outcome 
measures for progressive MS has been more difficult. This 
difficulty arises from the varied manifestations of progres-
sive MS (motor, sensory, coordination, cognitive, etc.), 
their slow rate of evolution, and difficulties in their quanti-
tative measurement. There are two main pathways to solv-
ing this challenge: refinement of existing outcome measures 
and development of new outcome measures.
Of the existing measures, The Kurtzke Expanded 
Disability Status Scale (EDSS)28 is the most common dis-
ability measure in MS trials. However, EDSS is an inher-
ently subjective assessment by a neurologist, has poor 
intra- and inter-rater reliability,29 and has poor precision. 
Refinements to the EDSS would likely improve its perfor-
mance, although many of its shortcomings are inherent to 
the tool and so are insurmountable.
The Multiple Sclerosis Functional Composite (MSFC) 
is the outcome of an international panel charged with 
replacing the EDSS.30 Advantages to the MSFC include its 
dynamic assessment of different functions relevant to MS 
(ambulation, arm function, and cognition) and improved 
statistical performance. Since the introduction of the 
MSFC, many validation studies have shown its clinical cor-
relations and predictive capacity. Despite these apparent 
advantages, the MSFC has not always been more sensitive 
than the EDSS in clinical trials. Equally important, the 
MSFC has not yet been accepted by regulators as an alter-
native to EDSS. As with EDSS, further refinement of the 
MSFC may improve its sensitivity, reliability, and respon-
siveness, although some shortcomings cannot be 
overcome.31
Important goals of MS therapies are to reduce symptom 
severity, improve function, and enhance quality of life. 
These are best evaluated through patient-reported outcome 
measures (PROMs), including global assessments of daily 
function and health-related quality of life (HRQL) meas-
ures.32 Regulatory interest in PROMs is growing, with 
guidelines emerging regarding the integration of PROMs 
into clinical trials.33 Efforts to improve clinical disability 
assessment in MS are already underway.31
Symptom management and 
rehabilitation
MS results in a diversity of symptoms, bringing increasing 
physical, psychological and emotional burden, particularly 
in the progressive stage of the condition. In spite of the 
introduction of effective disease-modifying treatments, 
symptom management and rehabilitation remain essential 
components of MS therapy, helping to alleviate the impact 
of disability and improve quality of life. Surprisingly, the 
rationale for specific pharmacological treatments for symp-
toms is frequently based on few trials with small patient 
numbers, often underpowered and unblinded.34 Recently, 
these shortcomings have begun to be addressed with a few 
well conducted studies, such as using cannabinoids35 and 
fampridine36 for motor symptoms. While cognitive deficits 
can now be clearly defined, fatigue remains more difficult 
to evaluate in trials because (a) less is known about the 
pathophysiology and (b) it may be influenced by psychiat-
ric factors, making quantitative characterization problem-
atic and often confounded. Depression and anxiety may 
respond well to either pharmacologic or cognitive behavio-
ral treatment.37–39 Symptom management in MS can be 
advanced in a number of ways. First, there should be tar-
geted research to improve our understanding of the patho-
logical mechanisms leading to symptom-related disability. 
This knowledge will allow more focused translational steps 
towards developing symptomatic therapies. Secondly, 
potential treatments should be assessed in rigorous, well 
designed trials that are sufficiently powered to establish 
beneficial effects, the optimum dosage, and short- and 
long-term side effects. Potential symptom interactions and 
confounding factors should be accounted for in the trial 
design. Ideally, studies should incorporate PROMs, surro-
gate pathological markers related to the particular symptom 
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under study and an assessment of cost-effectiveness. Third, 
further development of reproducible and responsive meas-
ures for different symptoms is needed.
Symptomatic treatment is normally part of a multidis-
ciplinary patient-centered approach that may involve 
rehabilitation. The relationship between neuroplasticity 
and rehabilitation is a critically important area for further 
research. Functional brain reorganization is well 
described in MS, showing increasing activation extent 
and the recruitment of additional areas, and hinting at the 
prospect of compensatory strategies.40,41 Some motor net-
works may be altered by training42 but there is a need to 
investigate if enhancing network plasticity may improve 
the outcomes of rehabilitation. Combining functional and 
structural imaging with cognitive rehabilitation may help 
develop treatments for cognitive impairment.43 Finally, 
applying brain–computer interface technology in patients 
with advanced MS may allow greater motor independ-
ence, communication and environmental control.44
Conclusions and future directions
Despite great progress in relapsing MS, much work is 
needed to achieve similar successes for progressive MS. 
There are a number of key areas of unmet need which are 
blocking treatment development in progressive MS. 
Although the international scientific community has made 
progress in some of these areas (Table 2), there have not 
been commensurate gains in progressive MS treatments. 
Tackling these issues will require an integrated, multi-dis-
ciplinary approach to enable effective translation of 
research into therapies. To this end, the International 
Progressive MS Collaborative is committed to engaging 
the MS research community through an international effort 
to fund a spectrum of research activities relevant to 
progressive MS with the ultimate goal of expediting the 
development of disease-modifying and symptom-relief 
treatments for progressive MS.
To address these five challenging areas, which currently 
impede the treatment of progressive MS, the International 
Progressive MS Collaborative commissioned five working 
groups, comprised of international experts, to identify 
specific strategies and potential lines of research that would 
overcome the barriers and realize the opportunities within 
each area. Following an international meeting in early 
2013, we anticipate that a call will be issued to address 
these opportunities. Potential sources of funding for this 
call include the existing research funding mechanisms of 
the member organizations of the International Progressive 
MS Collaborative as well as other partners (e.g., govern-
ment, industry). In addition, there will be an international 
fundraising effort led by the Multiple Sclerosis International 
Federation and financial support will be solicited from 
diverse channels around the world, including foundations, 
government, corporate, and private funding organizations.
Fostering global collaboration by the MS research com-
munity is a bold ambition, and potentially fraught with 
many challenges. Fortunately, the opportunities have never 
been as favorable as they are today, with unprecedented 
data on disease etiology, pathophysiology, and disease 
course. Furthermore, we can look to other diseases for 
inspiration. Collaborative efforts like the Forum for 
Collaborative HIV Research, the Alzheimer’s Disease 
Neuroimaging Initiative, and the Innovative Medicines 
Initiative, provide powerful examples of how collaboration 
can accelerate research among a diverse group of stake-
holders. While the collaborative efforts in progressive MS 
will almost certainly differ from those in other fields, the 
time is right for concerted action.
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